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ABSTRACT
The application of molecular biology to the discovery
of novel pathways to inhibit allergic tissue responses is
becoming a reality. Particularly promising approaches
are the use of vaccines and pharmacologic agents to
downregulate the polarized T Helper (Th)-2 lympho-
cyte response through enhancement of interferon-g
production. Selective inhibition of specific mediators,
such as interleukin (IL)-4, IL-5, IL-13 and eotaxin,
should lead to a new class of anticytokine therapeutic
agents. At the cellular level, more effective inhibition
of mast cell activation and strategies to remove IgE as
the triggering stimulus hold promise. With the discov-
ery of susceptibility genes for allergic disease, the next
decade is likely to witness substantial further develop-
ments in this field, with a strong focus targeted on
induction mechanisms and disease prevention. If the
current epidemic of allergic disease continues, then
there is a strong incentive to identify those environ-
mental factors that are responsible so that appropriate
interventions can be introduced. These may include
alterations to the maternal and infant diet to program
the developing immune response or, in genetically 
susceptible individuals, the early introduction of a
protective vaccine to reset the T lymphocyte balance
more in favour of a Th-1 response. In this regard, the
development of cytosine and guanosine nucleotide
repeats and antigen-specific DNA vaccines look espe-
cially promising. In established allergic disease, the
task of reversing sensitization is daunting. Safer and
more efficacious allergen vaccines, whether using
DNA or peptide approaches, offer the most promising
approach for fundamentally changing the allergic
immune response. Patients would also greatly benefit
from more effective and orally active mast cell
inhibitors and small molecules that could either
remove IgE or effectively interrupt its capacity to signal
through its cell surface receptors. In the meantime, the
epidemic of allergic disease requires urgent attention,
not only in the provision of specialist centers for 
providing accurate diagnosis and for administering
treatment (including immunotherapy), but in a clear
recognition that these disorders are caused by changing
environmental factors and, as a consequence, deserve
attention at the level of public health.
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INTRODUCTION
When John Bostock first described hay fever in 1819, the
condition was rare and restricted to the privileged class. As
we approach the turn of the century, allergy has reached
epidemic proportions with almost one in two people in the
developed world exhibiting an allergic response to one or
other common environmental factors. Most allergic dis-
eases are linked to atopy, the predisposition to generate
the allergic antibody IgE to common environmental
agents. Because IgE is able to sensitize mast cells any-
where in the body, atopic individuals frequently express
disease in more than one organ. Although current treat-
ments are able to control symptoms, allergy still causes
appreciable misery. There is urgent need for novel
approaches to be developed to more effectively treat aller-
gic responses and prevent their occurrence. The present
review focuses on some exciting new developments in the
field based on a clearer understanding of the underlying
cellular and mediator mechanisms and how the human
interacts with the changing environment. Strategies based
on blocking key signaling cytokines, removing IgE, inhibit-
ing mast cells and provoking both non-specific and
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specific immune protective responses will be discussed.
The introduction of molecular biology and genetics into
the design of novel therapeutics over the next two
decades will undoubtedly revolutionize the way these dis-
orders are managed.
Populated-based studies have revealed large geo-
graphical differences in the prevalence of allergic dis-
ease, with countries such as the UK, Australia and New
Zealand having figures 10–15-fold higher than central
and eastern Europe and Asia. Although atopic disorders
show strong heritability, it is differences in the environ-
ments that are likely to account for geographical
variations. Also of particular concern is the rising trend in
allergic disorders, both in the developed and developing
world. The increase has been especially noticeable in the
past two decades, predominantly affecting the young and
linked to a western-type lifestyle. Based on careful epi-
demiologic studies, changes to maternal and infants
diets, reduced exposure to antibiotics in infancy, avoid-
ance of indoor air pollutants (especially cigarette smoke)
and aeroallergens have all been suggested as steps to
reverse the rising trends.1
Current treatment options for allergic diseases are
based on allergen avoidance and the use of cortico-
steroids to control inflammation, and antihistamines and
sympathomimetics to treat symptoms. Allergen immuno-
therapy (desensitization) is also effective for some allergic
disorders (e.g. pollenosis, insect allergy), but not others
(e.g. eczema, food allergy). Central to an understanding
of how susceptible (atopic) individuals develop IgE
against certain environmental factors is a knowledge of
how the immune system recognizes and responds to the
offending agents. This involves uptake and processing 
of allergens, usually at a mucosal surface, by dendritic
cells and subsequent presentation of a small peptide to
naïve T lymphocytes.2 In those destined to develop an
allergic response, naïve T cells differentiate to a subtype
designated T helper (Th)-2, which secretes a group of
messenger proteins or cytokines responsible for switching
B lymphocytes to produce IgE, and the involvement of
mast cells, basophils and eosinophils. In contrast, Th-1
responses drive protective cell-mediated immunity and
also inhibit Th-2 responses by their release of the cytokine
interferon (IFN)-g (Fig. 1).
INHIBITING ALLERGEN SENSITIZATION
Because most atopic disorders are acquired early in life,
there is great interest in identifying those environmental
factors that lead to Th-2 polarization and the emergence
of allergic disease with a view to primary prevention. In
children destined to become allergic, there is impaired
production of IFN-g by their circulating T lymphocytes at
birth, which persists into late childhood.3 Thus, a possible
explanation for the protective effects of exposure to bac-
teria or their products during the period when sensi-
tization occurs in early life is their action to increase
IFN- g production.4 This concept has given rise to the
‘Hygiene Hypothesis’, in which changes to infant diets,
the early use of antibiotics and reduced exposure to bac-
terial products predisposes to the persistence of Th-2
responses in childhood.5 It follows that one approach to
treating allergy would be to take advantage of the capa-
city of Mycobacteria to evoke strong interleukin (IL)-12
and, consequently, IFN-g production as in the case of the
soil saprophyte Mycobacterium vaccae, because it is not
a human pathogen.6 Clinical trials of this ‘vaccine’ for
rhinitis and asthma are in progress with early results
revealing efficacy.7
Dendritic cells of vertebrates have evolved a defence
mechanism that detects bacterial DNA through their
excess of unprotected cytosine and guanosine nucleotide
repeats (CpG) and offers a possible explanation for the
protective action of bacteria on Th-2 responses.8 Synthetic
DNA containing CpG motifs are recognized as danger
signals by receptors on dendritic cells that serve to direct
the T lymphocyte response in a Th-1 way by inducing 
IL-12 release, which enhances IFN-g production (Fig. 1).9
Recent murine studies show that CpG DNA can be used
alone or with antigen to induce Th-1 responses even in the
presence of a pre-existing Th-2 response.9 Human studies
in allergic rhinitis and asthma are being initiated.
INHIBITING IgE RESPONSES
Cross-linkage of the major affinity receptor for IgE
(Fce R1) through allergen binding to cell surface IgE is the
principal way in which allergens activate mast cells and
basophils for mediator secretion. The Fce R1 comprises
an a chain (Fce R1a ), which binds with strong affinity to
IgE, two Fce R1b chains responsible for cell signaling 
and a g chain that regulates receptor signaling. Although
there is debate about the precise molecular interaction
between IgE and Fce R1a , mouse monoclonal antibodies
(mAbs) have been produced that inhibit IgE binding to
Fce R1a but are unable to cross-link IgE bound to mast
cells or basophils and, therefore, fail to initiate mast cell
activation.10 When administered intravenously to atopic
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individuals, chaemeric (CGP 51901) or fully humanized
(E25) anti-IgE mAbs rapidly reduce circulating IgE 
to almost undetectable levels. In patients with allergic
asthma, nine weekly injections of E-25 mAb almost 
abolished the early (mast cell mediated) and late
(inflammation mediated) bronchoconstriction to inhaled
allergen.10 The mAb E-25 is also effective in controlling
clinical asthma, reducing exacerbations and oral corti-
costeroid requirement by 50% as well as improving
baseline lung function and reducing bronchodilator
use.10 Anti-IgE therapy has also proven to be efficacious
in allergic rhinitis.11 Clinical trials are in progress to
assess its efficacy in severe asthma.
In 1990, a decapeptide within IgE was shown to elicit
antibodies that blocked anaphylactic histamine release in
rabbits.12 One report has shown that this ‘vaccine’ is effi-
cacious against food allergy in humans,13 but a further
clinicial trial has failed to confirm this. Nevertheless,
other peptide sequences of the Fce R1-binding regions of
IgE offer great promise as anti-allergic vaccines14 and,
while some concern had been expressed that removal 
of IgE will reduce protection against parasites, animal
studies have so far failed to show this.
INHIBITING MEDIATOR RELEASE OR THEIR
EFFECTS
Although sodium cromoglycate has been regarded as
the archetypal anti-allergy drug, its relatively low effi-
cacy for inhibiting mast cells has been problematic. The
identification of proteins that contain immunoreceptor
tyrosine-based inhibitory motifs (ITIM; e.g. mast cell-
associated function antigen (MAFA), gp 49B1 and
Fc g RIIB receptors) provide new targets for mast cell 
inhibition.15 These cell-surface proteins associate with
Fc e RI within membrane ‘rafts’ and potently inhibit mast
cell activation by recruiting enzymes to dephosphorylate
Fc e RI b and Fc e RI g chains to interrupt IgE signaling.
The clear involvement of inflammatory mediators,
such as histamine, prostaglandins and leukotrienes,
which interact in allergic responses, has stimulated the
development of drugs that either inhibit their formation
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Fig. 1 The altered cytokine balance in allergic disease. IL, interleukin; Th-2, Th-1 T helper 2 and 1 cells, respectively; GM-CSF,
granulocyte–macrophage colony stimulating factor.
or selectively block their effects. An alternative approach
is to neutralize mediators once they have been released,
similar to the binding and inactivation of cytokines by
soluble receptors. In order to minimize tissue reactions,
hard ticks have evolved proteins in their saliva that do
just this. Rhipicephalus appendiculatus is a tick that
secretes saliva in its three histamine-binding proteins
(Ra-HBP). Histamine-binding protein-2 (RaHP2) has two
internal histamine binding pockets and a folding pattern
not dissimilar to other lipocalins that exist to bind small
molecular weight chemicals.16 The Ra-HBP1, Ra-HBP2
and Ra-HBP3 have been cloned and the recombinant
proteins expressed. In vitro, they inhibit mast cell media-
tor induced-contraction of sensitized tissues and one
such molecule is currently in clinical trials. It is highly
likely that other selective mediator inhibitors are awaiting
discovery in tick saliva, the activity of which could be
harnessed to create novel anti-allergic agents.16
The recent discovery that many allergens possess
enzymatic activities raises the issue as to whether such
biological properties create some advantage for the
molecules in becoming sensitizing agents. The cysteine
protease of the dust mite allergen Der P1 can cleave
human low-affinity IgE receptor (Fce R2, CD23; involved
in IgE regulation), IL-2 receptor (involved in T-cell activa-
tion) and occludin (a key protein in epithelial tight
junctions), which could lead to an increase in local IgE
synthesis, Th-2 polarization and penetration of allergen
into mucosal tissues.17 The importance of proteolytic
enzymes in enhancing sensitization is now being realized
as is the potential benefit from blocking these activities
with selective inhibitors, such as PTL 11028.18
TARGETING PRO-ALLERGIC CYTOKINES
Interleukin-4 and its homologue IL-13 are pivotal in
regulating the allergic phenotype (Fig. 1) and produce
their cellular effects through the signal transducer and
activator of transcription (STAT)-6.19 Interleukin-4 (but
not its homologue IL-13) is essential for maintaining
the Th-2 T cell phenotype, although for many of the
other functions either cytokine is effective (Table 1). If the
genes for IL-4, IL-13 or STAT-6 are deleted in mice, IgE
production and antigen-induced airway inflammation
are severely attenuated. In the double IL-13/IL-4 knock-
out mouse IgE production is abolished. While human-
ized blocking mAbs against IL-4 have been developed,
the preparation of a recombinant soluble form of the
human IL-4 receptor a chain without its transmembrane
and cytoplasmic regions (sIL-4r) has shown efficacy in a
mouse model of immediate hypersensitivity20 and, more
recently, in atopic asthma.21 Interleukin-13 is produced
in large amounts by asthmatic airways and has been
incriminated as an important cytokine in mouse models
of asthma. Not only is it involved in IgE regulation, but it
is also profibrogenic and induces mucus metaplasia of
the epithelium.22,23 Although IL-13 binds to one of the
two subtypes of IL-4r (IL-4a /IL-13 a ), it will not be recog-
nized by soluble IL-4r. Thus, an alternative approach to
inhibit both IL-4 and IL-13 functions has been to use a
double mutant of IL-4 (Arg-121-Asp and Tyr-124-Asp;
BAY 16-9996) which is an antagonist.24 Administration
of the IL-4 double mutant to mice completely prevented
the allergic antibody response as well as cutaneous ana-
phylactic responses on exposure to sensitizing antigen.25
In IL-4- or IL-13-responsive cells, STAT-6 itself is also a
selective target, inhibition of which will prevent signaling
by both IL-4 and IL-13.19
Interleukin-5 is a Th-2 cytokine that is considered 
essential for the recruitment of eosinophils in allergic
inflammatory responses (Fig. 1; Table 2). In animals,
administration of an anti-IL-5 blocking mAb inhibits
eosinophil recruitment from the bone marrow into
tissues, resulting in ablation of the late-phase reponse to
inhaled antigen.26 Recently, a humanized anti-IL-5 block-
ing mAb (SB-240563) has become available, which,
when administered to atopic asthmatic subjects as a
single intra-venous dose, reduced both blood and sputum
eosinophils but, surprisingly, failed to inhibit either the
allergen-provoked late-phase bronchoconstriction or
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Table 1 Pro-allergic functions of interleukin-4 and -13
Interleukin-4 Interleukin-13
T helper-2 cell polarization + –
B cell IgE switching + +
Upregulation of vascular cell 
adhesion molecule + +
Upregulation of mucus genes + +
Increased fibroblast proliferation
and collagen production + +
Decreased monocyte functions + +
Table 2 Proallergic functions of interleukin-5
Maturation of eosinophils
Priming of eosinophils for enhanced mediator secretion
Chemoattraction of eosinophils
Protection of eosinophils from apoptosis
airway hyperresponsiveness.27 This result questions the
association between IL-5 secretion and induced eosino-
phil recruitment as being obligatory for the human
late-phase allergic response, but does not reduce inter-
est in this approach for treating chronic eosinophil-
mediated disorders that rely on IL-5.28
The recent discovery that a cluster of cytokines
belonging to the CC chemokine family, which includes
three eotaxins, MCP-1, -3 and -4 and RANTES, are
powerful eosinophil chemoattractants using a common
cell surface receptor (CCR-3), opens up another impor-
tant target for intervening in allergic disease.28 A mAb
directed against CCR-3 blocks eosinophil migration.29
Human mAbs against eotaxin itself are being devel-
oped, although, on account of chemokine redundancy,
this will probably be a less effective strategy than
developing selective antagonists against the CCR-3
receptor itself. Using bacteriophage expression libraries
and combinatorial chemistry, highly selective peptide
and non-peptide CCR-3 receptor antagonists are being 
discovered. Recent research indicates that CCR-3 and
IL-5r ligands work co-operatively to recruit eosinophils
into target tissues.28
ALLERGEN-SPECIFIC IMMUNOTHERAPY
The aim of immunotherapy is to vaccinate with allergen or
its derivatives to produce selective inhibition of allergen-
specific responses. While undoubtedly efficacious in a
number of serious allergic disorders (e.g. insect or peni-
cillin anaphylaxis), care has to be exercised in order not
to provoke local and systemic anaphylactic reactions.
Indeed, in some countries, such adverse reactions have
limited the uptake of immunotherapy as a therapeutic
option. In an attempt to circumvent this, many allergens
have been cloned and mutated to reduce interactions
with IgE without changing the epitopes responsible for
the development of T cell tolerance. Strategies are also
in place to develop peptides that will inhibit T cell
responses to allergens but fail to trigger IgE-mediated
mast cell responses. Because immunotherapy is thought
to be protective, in part, by inducing a Th-1 IFN-g
(Fig. 1),30 attempts to enhance the efficacy of allergen-
immunotherapy by generating allergen peptides in 
M. vaccae are being actively pursued.
A further breakthrough to intervene in allergy has
been the use of antigen-selective DNA vaccines to
induce allergen synthesis and a powerful protective
immune response in the host. Leong et al. have cloned a
major peanut allergen into a synthetic vector in which
the DNA is protected from digestion by chitosan, a natu-
rally occurring polysaccharide used for the controlled
intenstinal delivery of many pharmaceutical agents.31
After ingestion, nanoparticles of the polysaccharide
adhere to intestinal epithelial cells to facilitate the uptake
of peanut-specific DNA. When administered orally to
mice, this ‘vaccine’ protected animals against both sen-
sitization and anaphylaxis upon subsequent peanut
challenge. A critical question to answer is whether DNA
vaccines can produce tolerance if given to an already
sensitized subject. It is encouraging that at least one
controlled study has shown that sublingual administra-
tion of a grass pollen extract is beneficial in established
seasonal allergic rhinitis.32
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